Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2025Open Access

Optimizing Dose Conversion From IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ZAZeyar Mohammed AliBFBeatriz Fernández-AlarcónPFPere Fontova

Discussion

Loading...

Member takes

Overview

Population pharmacokinetic modeling reveals impact of genetics on tacrolimus dose conversion in renal transplant recipients, suggesting tailored strategies for effective treatment.

Key Points

  • Enhanced bioavailability of LCP-Tac necessitates a lower dose conversion ratio from IR-Tac in renal transplant recipients.
  • CYP3A5 genetic polymorphism significantly influences clearance rates and dose requirements between formulations.
  • A two-compartment pharmacokinetic model effectively characterizes differences in absorption between LCP-Tac and IR-Tac.
  • Adjusting tacrolimus doses based on genetic profiles improves the management of immunosuppressive therapy in transplant patients.

Cite This Study

Ali et al. (2025) studied this question.

synapsesocial.com/papers/689a0c65e6551bb0af8cfad0https://doi.org/10.20944/preprints202507.2483.v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Optimizing Dose Conversion from IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling Study2025
  2. 2Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP Formulation2025
  3. 3Impact of Azole Antifungals on the Conversion Ratio of Immediate-release Tacrolimus to LCP-Tacrolimus Tablets in Non–kidney Solid Organ Transplant Recipients2026
  4. 4Guiding the starting dose of the once-daily formulation of tacrolimus in “de novo” adult renal transplant patients: a population approach2024 · 3 citations
  5. 5Extended-Release Tacrolimus Versus LifeCycle Pharma Tacrolimus in Kidney Transplant Recipients: A Switch Study2026